Lantheus (NASDAQ:LNTH) Updates FY 2025 Earnings Guidance

Lantheus (NASDAQ:LNTH - Get Free Report) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 6.600-6.700 for the period, compared to the consensus estimate of 7.050. The company issued revenue guidance of $1.6 billion-$1.6 billion, compared to the consensus revenue estimate of $1.6 billion.

Lantheus Trading Up 1.8 %

LNTH traded up $1.42 during trading on Friday, hitting $81.86. 1,561,278 shares of the company's stock were exchanged, compared to its average volume of 968,057. The stock has a 50 day moving average price of $99.57 and a 200 day moving average price of $94.36. Lantheus has a 1 year low of $75.00 and a 1 year high of $126.89. The firm has a market cap of $5.61 billion, a P/E ratio of 13.62 and a beta of 0.23.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The company had revenue of $372.76 million during the quarter, compared to analyst estimates of $377.37 million. During the same quarter in the prior year, the company posted $1.69 earnings per share. The firm's revenue for the quarter was up .8% on a year-over-year basis. Analysts forecast that Lantheus will post 6.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have issued reports on LNTH. JMP Securities reaffirmed a "market outperform" rating and issued a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. Truist Financial dropped their price target on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a research note on Thursday. B. Riley decreased their price objective on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research report on Friday, March 21st. Finally, StockNews.com upgraded Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, Lantheus has an average rating of "Buy" and a consensus target price of $132.67.

Insider Transactions at Lantheus

In related news, CFO Robert J. Jr. Marshall sold 10,000 shares of the firm's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the transaction, the chief financial officer now directly owns 113,860 shares in the company, valued at $11,445,207.20. This trade represents a 8.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares of the company's stock, valued at approximately $41,551,645.65. This represents a 10.76 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 63,109 shares of company stock valued at $6,016,046. Insiders own 2.00% of the company's stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.